BioStem Technologies Inc (ID) (BSEM)

131 days with the promo badge

33 days with stock promo badge. Withdrew the Form 10. Alt Reporting. Obviously fraud is suspected. Most likely result Caveat Emptor.

CE???

Stock Promo, most likely a CE result.

What a shame. BSEM appeared to be a good stock. Couple of problems now though: They don't work hard to keep investors informed. They didn't have the right people handling their "uplisting". They didn't approach the Medicare reimbursement path quickly and properly. And they now have several competitors already receiving Medicare reimbursement. That means they still have a lot of work to do and have to be very careful with their pricing and reputation in order gain practitioners already being serviced by the competition. Tough nut to crack but have to be realistic. They were a $28 stock back in the day when they were hardly more than a good idea. This just goes to show you how many factors there are in being a successful company. They are definitely behind the eight ball now! Does anyone have some good news?

Looks like it's gonna be a good Week.

$BSEM Back over $20 next Week!

$BSEM Zacks: BSEM Continues to Exceed Expectations
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

Strong day yesterday +1.10 (+7.24%) ~ Very undervalued with all that is happening here! Nice afternoon move Thursday... Looking for continuation today...$BSEM

My personal goal here is 100% from here ~$15.25... That would be a huge gain... Looking 1-2 months for Target to hit...

$BSEM Continues to Exceed Expectations ~ Price Target Now $32.50
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future. The vision management has for the company’s products and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand. As such, we urge investors to take a good look at BSEM.

$BSEM NASDAQ Up-listing just a matter of time! Application was filed in Sept so it should be approved any time now! The NASDAQ listing will allow may new Institutions to be able to buy $BSEM. That will be huge!

$BSEM Continues to Exceed Expectations ~ Upgrades Price Target ⚡️
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

$BSEM Medicare Issues Shouldn’t Impact BioStem
https://finance.yahoo.com/news/bsem-medicare-issues-shouldn-t-160500411.html

We reiterate our belief in the direction of BSEM and urge investors to avoid succumbing to kneejerk responses and message board rumors. The vision and focus of BSEM is impressive and gives us confidence that BSEM will continue to have its products covered by Medicare and continue to grow its revenues.

Think we bounce soon here...

Looking for a nice rebound day here...$BSEM

$BSEM Zacks Increases Price Target to $32.50 Per Share. Very Undervalued Here!✈️

$BSEM Chart back on uptrend from recent lows. MACD crossed bullish yesterday and accumulation getting stronger. Investors are accumulating shares here! Looks headed back to recent highs. 📈

$BSEM BioStem Technologies: The Superior Stem Cell Investment Opportunity
Link: https://www.wallstreetpr.com/biostem-technologies-bsem-the-superior-stem-cell-investment-opportunity-58143?utm_medium=social&utm_source=twitter&utm_campaign=simplified&utm_content=simplified8b5cc

Bigger than normal volume.  News soon? 

Solid close Friday.  Looking for continuation 

New Growth Report BioStem Technologies, Inc. (OTC: BSEM)

BSEM Key Highlights


Completed an extensive two-year audit in preparation for moving BSEM to a national exchange. (NASDAQ or NYSE)
Recently released their Q1 earnings, which shocked the market with revenues totaling $41 million in the first quarter of 2024.
First positive net income of over $4.4 million in the quarter.
Analyst Target $23.75 representing a 153% upside from the current price of $9.38
Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach $18.4 billion by 2028.

Take a minute to look at the full analysis and disclosures >>> https://tradersnewssource.com/wp-content/uploads/2024/06/TNS-BSEM-growth-report-6-27-24.pdf

#BioStem #BSEM #WoundCare #Biotech #Healthcare #StockMarket

I’m watching $BSEM, regenerative medicine is hot, the stock is cheap compared to peer group companies, read their research report here $SINGT $FFIE $SLNA $REBN $TTOO
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_05152024_BSEM_Sorensen.pdf

Nice chart

Where's this going?

Let's see that end of week surge today $

Let's see that bounce tomorrow $

Charts setting up nicely here imo

Volumes picking up $

Yep we're primed for it $

TRENDING STOCK CHART ANALYSIS



$BSEM

Go time imo

Nice movement today! Creeping towards those highs $

Top the morning $BSEM

3.50s + coming , clear skies when they fall

Absolutely! Solid close $

structured well so it can move fast

good target

Looking for that next leg up $ thru 3.40s

Seeing a nice little uptrend these past few months BSEM

Due for something

Fresh week

Think she ready

Overdue imo

Been quiet. Time to wake up?

Good Morning $BSEM

https://www.globenewswire.com/en/news-release/2022/08/22/2502499/0/en/BioStem-Technologies-Reports-Second-Quarter-2022-Operating-and-Financial-Results.html

Conference Call Details

Date: Monday, August 22, 2022
Time: 4:30 pm EDT
Webcast Link:
https://event.on24.com/wcc/r/3911284/BE0F9AAF8531A6FE6131F4DBA6ADCF55
Conference ID: 4373739
Participant Toll-Free Dial-In Number: 1 (888) 880-2204
Participant Toll Dial-In Number: 1 (646) 960-0414

$BSEM BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022Press Release | 06/17/2022

POMPANO BEACH, FLORIDA, June 17, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading, innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies will be hosted on Benzinga’s All Access show, which airs on Benzinga TV and Benzinga’s YouTube channel on June 17 2022, at 10:20 AM EST.

BioStem Technologies CEO Jason Matuszewski will be interviewed and provide updates on the latest developments in BioStem’s business growth and portfolio of products. A link to the YouTube broadcast will be available in our investor relations news portal at the below link:

https://www.biostemtechnologies.com/news.

Or watch or listen live to the All-Access broadcast via the Benzinga YouTube channel in the link below:



About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes VENDAJE®, VENDAJE® AC, and VENDAJE® OPTIC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

Investor Relations:
info@biostemtech.com
(954) 380-8342